Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

NCT00521053 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Program With Nivolumab to Treat Melanoma

NCT02142218 ·Status: NO_LONGER_AVAILABLE

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma

NCT02297529 ·Status: NO_LONGER_AVAILABLE

An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

NCT06590480 ·Status: NO_LONGER_AVAILABLE

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

NCT05402059 ·Status: UNKNOWN

A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients

NCT07068074 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

NCT04960891 ·Status: AVAILABLE

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

NCT03199846 ·Status: COMPLETED

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824 ·Status: UNKNOWN ·Phase: PHASE2

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676 ·Status: COMPLETED ·Phase: PHASE1

SBRT as a Vaccination for Metastatic Melanoma

NCT04042506 ·Status: WITHDRAWN ·Phase: PHASE2

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

NCT02186249 ·Status: NO_LONGER_AVAILABLE

A Study of RO5185426 in Patients With Metastatic Melanoma

NCT01248936 ·Status: COMPLETED ·Phase: PHASE2

RAD001 Plus Bevacizumab in Metastatic Melanoma

NCT00591734 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704 ·Status: COMPLETED ·Phase: PHASE3

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

NCT04146324 ·Status: COMPLETED

Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)

NCT02083484 ·Status: NO_LONGER_AVAILABLE

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

NCT06743126 ·Status: RECRUITING ·Phase: PHASE3

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

NCT05115006 ·Status: COMPLETED

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

NCT00057616 ·Status: COMPLETED ·Phase: PHASE3

Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma

NCT01864759 ·Status: COMPLETED ·Phase: PHASE1

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

NCT03064763 ·Status: COMPLETED ·Phase: PHASE1